Franz Humer, chairman of Roche Holding AG, talks with Bloomberg's Francine Lacqua and Mark Barton from Basel about the Swiss drugmaker's offer to buy the rest of Genentech Inc. for $43.7 billion to gain the largest U.S. maker of cancer medicines. Investors in South San Francisco, California-based Genentech would get $89 a share in cash, 8.8 percent more than the July 18 closing price, Roche said today. Roche already owns 56 percent of Genentech and markets many of its treatments.
Rating:  (0 ratings) |
Views: 81 |
Added: Jul 21, 2008 |
| Category: Business |
|
|
|